Background Ferroptosis is an iron-dependent, lipid peroxide-mediated cell death that may be exploited to selective elimination of damaged and malignant cells. Recent studies have identified that small-molecule erastin specifically inhibits transmembrane cystine–glutamate antiporter system xc−, prevents extracellular cystine import and ultimately causes ferroptosis in certain cancer cells. In this study, we aimed to investigate the molecular mechanism underlying erastin-induced ferroptosis resistance in ovarian cancer cells. Methods We treated ovarian cancer cells with erastin and examined cell viability, cellular ROS and metabolites of the transsulfuration pathway. We also depleted cystathionine β-synthase (CBS) and NRF2 to investigate the CBS and NRF2 dependency in erastin-resistant cells. Results We found that prolonged erastin treatment induced ferroptosis resistance. Upon exposure to erastin, cells gradually adapted to cystine deprivation via sustained activation of the reverse transsulfuration pathway, allowing the cells to bypass erastin insult. CBS, the biosynthetic enzyme for cysteine, was constantly upregulated and was critical for the resistance. Knockdown of CBS by RNAi in erastin-resistant cells caused ferroptotic cell death, while CBS overexpression conferred ferroptosis resistance. We determined that the antioxidant transcriptional factor, NRF2 was constitutively activated in erastin-resistant cells and NRF2 transcriptionally upregulated CBS. Genetically repression of NRF2 enhanced ferroptosis susceptibility. Conclusions Based on these results, we concluded that constitutive activation of NRF2/CBS signalling confers erastin-induced ferroptosis resistance. This study demonstrates a new mechanism underlying ferroptosis resistance, and has implications for the therapeutic response to erastin-induced ferroptosis.

As a transcription factor, the role of CASZ1 in different entities is inconsistent. Glioma is one of the leading causes of cancer death worldwide. Its prognostic relevance and biological functions in glioma remain obscure. We focused on the role, mechanism, and prognostic value of CASZ1 in glioma cells. Herein, CASZ1 was identified as a novel potential oncogene in glioma tissues from GEO and TCGA datasets. CASZ1 was highly expressed in glioma tissues, predicting poor prognosis in glioma patients. Knockdown of CASZ1 inhibited proliferation and invasion in vitro, whereas upregulation of CASZ1 presented opposite results. Overexpression of CASZ1 increased transcriptional process of target gene p75NTR. CASZ1 was the potential transcriptional regulators for p75NTR. In addition, the p75NTR expression is essential for CASZ1 to exert its function as an oncogene. Our findings indicate that highly expressed CASZ1 in glioma cells acts as a pro-oncogene factor in gliomas via regulating transcriptional process of target gene p75NTR, which was identified as an unfavorable prognostic marker in patients with gliomas. CASZ1 is expected to become a novel target for the treatment of gliomas.

No abstract

The low response rate to immunosuppressant is mainly due to the lack of adequate knowledge about the tumor microenvironment (TME) and screening biomarkers for gliomas. We aimed to identify the promising immune biomarkers and new immune classification of glioma. In this study, multiple‐immune algorithms were used to calculate immune‐infiltration scores. Unsupervised and supervised machine learning methods were used to perform the classification. We observed that OLFML3 overexpression was indicated in gliomas and linked to poor prognosis. OLFML3 knockdown inhibited proliferation, invasion and increased the sensitivity of glioma cells to temozolomide. OLFML3 expression could also reflect the aberrant immune status. Based on the immune‐related signature, patients were divided into three immune subtypes via consensus clustering. Patients with C2 subtype presented poorer prognosis and shorter progression free survival than patients with other two subtypes. The TME patterns among subtypes were different. C2 and C3 subtypes are the immune‐inflamed and immune‐desert tumors, respectively. Additionally, compared with C3 subtype, patients with C1/C2 subtypes were more likely to respond to immunotherapy. The pRRophetic algorithm indicated patients with C1/C2 subtypes were more resistant to temozolomide, but sensitive to paclitaxel and cisplatin. To conclude, OLFML3 overexpression affects glioma cell proliferation, invasion, and TMZ sensitivity and has been proved to be an independent prognostic‐ and immune‐related biomarker. Additionally, the novel immune subtype's classification could provide the prognostic and predictive predictors for glioma patients and may guide physicians in selecting potential responders.

Background: Previous studies have reported the critical roles of tumor cells and the tumor microenvironment in tumor prognosis and immunotherapeutic response. However, how Tenascin-XB (TNXB) expression relates to glioma prognosis and to the levels of tumor-infiltrating immune cells in various cancers has remained elusive. Therefore, this work aimed to investigate the expression, prognostic value, biological function and correlation between TNXB expression and the levels of tumor-infiltrating immune cells in glioma tissues.Methods: First, we explored TNXB expression in glioma tissues by using online biological databases. Second, we assessed the clinical importance of TNXB expression with chi-squared tests, Cox regression and Kaplan-Meier curve analyses. Third, we examined the relationship between TNXB expression and the levels of tumor-infiltrating immune cells in glioma tissues in an online database. Additionally, we assessed the associations of TNXB expression with genetic markers of immune cells and common immune-checkpoint molecules.Results: Elevated TNXB expression in glioma tissues correlated with tumor grade, according to several databases. Elevated TNXB expression was significantly associated with negative clinicopathological manifestations and poorer prognosis, on the basis of TCGA (n=510) data. Furthermore, univariate and multivariate Cox regression indicated that TNXB was an independent indicator of glioma prognosis. Pathway enrichment analyses suggested that TNXB participates in the immune response, humoral immune response and interferon-gamma-mediated signaling pathways. Importantly, TNXB expression was significantly associated with higher levels of tumor-infiltrating immune cells in diverse cancers. Furthermore, TNXB expression was strongly associated with genetic markers of immune cells and common immune-checkpoint molecules (e.g., PD-1, PD-L1, CTLA4, TIM-3, LAG3, PDCD1LG2, TIGIT and Siglec-15).Conclusions: TNXB expression correlates with poorer prognosis and higher levels of tumor-infiltrating immune cells in several cancers. In addition, TNXB expression is likely to contribute to the regulation of dendritic cells, exhausted T cells, regulatory T cells and tumor-associated macrophages in gliomas. Consequently, TNXB may serve as an important prognostic marker and may play an immunomodulatory role in tumors.

Background C5AR2 is recognized as a proinflammatory molecule and activates the inflammatory response in multiple disorders. However, little has been reported on C5AR2 in glioma. This study sought to explore its expression, biological function, and association with clinical pathological indicators, prognosis, and immune infiltration levels in glioma through glioma cohorts. Methods A cohort of 657 patients was screened from the Chinese Glioma Genome Atlas (CGGA). χ2 test was performed to calculate the difference of classified variables. Cox proportional hazard regression modeling was used to identify independent prognostic indicators of glioma patients. A survival plot was generated by the Kaplan–Meier method. The immune cell infiltration score of glioma patients was calculated by TIMER algorithm. Results We observed that high expression of C5AR2 was strongly associated with malignant clinical indicators in 657 patients with glioma, and patients with high C5AR2 expression had worse prognoses. Multivariate Cox analysis showed that C5AR2 could be a new independent prognostic indicator for glioma patients. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis revealed that C5AR2 overexpression correlated with multiple inflammatory and immune biological processes. Additionally, high C5AR2 expression was strongly associated with higher abundance and marker gene expression of multiple tumor immune cells in low‐grade glioma. Finally, a model was constructed to improve the prognostic evaluation of glioma patients. Conclusions The C5AR2 gene is highly expressed in gliomas and is significantly associated with clinical indicators of malignant progression in glioma patients. In glioma, patients with high C5AR2 expression displayed a worse outcome. In glioma tissues, the expression level of C5AR2 highly correlated with the abundance of tumor immune cell infiltration. Additionally, GO and KEGG enrichment analysis revealed that C5AR2 expression may be involved in a variety of immune and inflammatory biological processes.

In part due to a lack of early symptoms and robust screening strategies, ovarian cancer is often diagnosed in later stages and has the highest worldwide mortality among gynecologic malignancies. Tumor markers CA125 and HE4 are effective in the diagnosis of ovarian cancer; however, there is a need for prognostic tumor markers for ovarian cancer. Circulating tumor cells (CTCs) detected in liquid biopsy may correlate with prognosis of several cancers and can be used in early evaluation of recurrence. Despite numerous studies, there is conflicting evidence in the prognostic significance of CTCs in ovarian cancer.This meta-analysis aimed to evaluate whether detection of CTCs in patients with ovarian cancer had adverse survival outcomes with consideration of sampling time, treatment, enrichment method, and detection method. A literature search across the electronic databases of Embase, PubMed, and Cochrane Library was conducted in July 2020, and clinical trials that analyzed CTCs in ovarian cancer patients along with survival outcomes including progression-free survival (PFS) and overall survival (OS) were included. Techniques used for CTC enrichment and detection involve various enrichment approaches (physical and immunological methods) and detection approaches (immunocytological and molecular biological techniques). Protocol and clinicopathological characteristics were extracted along with survival outcomes from relevant articles. In the case that an included study did not have survival outcomes with hazard ratios (HRs) and 95% confidence intervals (CIs) for PFS and OS, statistical analyses were run on the Kaplan-Meier survival curves to obtain this information for analysis.A total of 15 studies, 2 clinical trials and 13 prospective studies, including 1285 patients with ovarian cancer were included in the final analysis. The results showed CTCs were not significantly associated with grades, stages, and lymph node metastasis (odds ratio [

No abstract